Application for clinical application of levolacetam sustained release tablets, a class 3.1 epilepsy drug of Huahai pharmaceutical

According to the public information, levetiracetam is mainly used for the treatment of localized and secondary systemic epilepsy The original research drug is Belgium United Chemical Enterprise (UCB S.A.) According to the clinical terminal statistics of Nanfang Institute, the global sales of levetiracetam ranked the second among antiepileptics in 2008-2012, with a compound annual growth rate of 56% In 2012, the sales volume of the product in domestic sample hospitals reached 78.77 million yuan, a substantial increase of 67% year on year CFDA website information shows that at present, there are three domestic manufacturers of levetiracetam ordinary tablets, namely Beijing New Pharmaceutical (002020 SZ), xinlitai (002294 SZ) and Chongqing shenghuaxi pharmaceutical In addition to Huahai pharmaceutical, about 10 other enterprises have applied for clinical approval of sustained-release preparations It is worth mentioning that after oral administration, the sustained-release preparation will release the drug slowly and at a non constant speed according to the requirements in the specified release medium Compared with the corresponding ordinary preparation, the administration frequency is lower than that of the ordinary preparation, and it can significantly increase the compliance of patients or reduce the side effects of the drug Huahai Pharmaceutical Co., Ltd is mainly engaged in Puli and sartan type hypertension APIs, and is actively transforming to preparations Domestic preparations are an important strategic layout of the company.